SlideShare une entreprise Scribd logo
1  sur  66
免 疫 缺 陷 疾 病 簡 介 郭和昌 醫師 高雄長庚兒童過敏免疫風濕科 July 2008 Waikiki beach, Hawaii
郭和昌醫師 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
免疫系統 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Source: National Cancer Institute   Ab MΦ complement
免疫缺陷 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Adapted from: Laura@Medimagery.com T cell response and B cell response
Primary vs. secondary exposure
Question 1   ,[object Object]
Q.  何時該懷疑免疫缺乏症  ? ,[object Object],[object Object],[object Object],[object Object],[object Object],Nelson 17th edition: p.681
北海道 - 小樽運河
東京 - 皇居二重橋
明治神宮 , 東京
 
 
北海道 - 小樽
 
北海道 - 函館山
北海道 - 函館山 - 百萬夜景
 
Question 2 ,[object Object]
進一步評估分三方面 ,[object Object],[object Object],[object Object],[object Object]
家族及個人病史 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
免疫系統理學檢查 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],免疫系統理學檢查
清溪川 =  李明博 總統
首爾 - 雪景
首爾 - 民俗村
 
 
為何有兩種蛋糕 ???
見微知著  ! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],免疫細胞的質與量均須考量  !!!
應該安排哪些免疫進階檢查  抽絲撥解 ,[object Object],[object Object],[object Object],[object Object]
吞噬細胞缺損篩檢 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Phagocyte function  Adhesion Migration Phagocytosis chemotaxis Respiratory burst
睡著了嗎 ?
Phagocyte evaluation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
NBT slide test ,[object Object],[object Object],[object Object],[object Object]
非洲皇冠鶴 Hyatt Regency and resort Maui, Hawaii
自在 Hyatt Regency and resort Maui, Hawaii
Swam Court, Hyatt Regency and Resort Maui, Hawaii
Swam Court, Hyatt Regency and Resort Maui, Hawaii
吞噬細胞缺陷 Delayed detach of umbilical cord >1 m Perianal abscess formation Granulation tissue (CGD) 反覆口腔潰瘍 , 牙齦肥厚
Pictures of CGD
Pictures of Hyper-IgE syndrome (Job syndrome)
抗體缺損篩檢 : ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
B cell  功能  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],B cell  功能
抗體缺乏 1.  出生 6 個月以後發生 2.  反覆呼吸道腸胃道感染 關節炎 Recurrent sinusitis  Pseudomonas infection  Ecthyma gangrenosum
T  細胞免疫缺損篩檢 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],T cell  功能
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],T cell  功能
細胞免疫缺乏 Invisible thymus Oral thrush  BCG infection Disseminated varicella infection
Delay type hypersensitivity Candida PPD Toxoid Mumps
Waikiki beach, Hawaii
Waikiki beach, Hawaii
Westin Resort, Hawaii
Kalakawa Ave. Hawaii
Hilo Hatis, Hawaii
補體免疫缺損篩檢 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],補體免疫缺損篩檢
補體功能
補體缺乏 淋病性敗血症, 多發關節炎 關節炎 Skin rash C2, C4  rashes C3  敗血症 C6 , 7, 8, 9  淋病關節炎
個案討論 ,[object Object],[object Object],[object Object],[object Object],[object Object]
歷屆考題  牛刀小試 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Thanks for your attention and comment !!!

Contenu connexe

En vedette

2016-02 Toxicidades de los nuevos fármacos en cáncer renal
2016-02 Toxicidades de los nuevos fármacos en cáncer renal2016-02 Toxicidades de los nuevos fármacos en cáncer renal
2016-02 Toxicidades de los nuevos fármacos en cáncer renalMartín Lázaro
 
Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...
Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...
Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...Peertechz Publications
 
免疫系統
免疫系統免疫系統
免疫系統a5589389
 
岡山スマホアプリ開発もくもく会 #oso2016
岡山スマホアプリ開発もくもく会 #oso2016岡山スマホアプリ開発もくもく会 #oso2016
岡山スマホアプリ開発もくもく会 #oso2016Ikki Takahashi
 
中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015
中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015
中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015CODE BLUE
 
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingdianecleverley
 
HEOR and HTA for Market Access and Value Propositions
HEOR and HTA for Market Access and Value PropositionsHEOR and HTA for Market Access and Value Propositions
HEOR and HTA for Market Access and Value PropositionsRobert Simons
 
20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業
20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業
20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業KodaiSakamotoChuo
 
New immune system of information security from CHINA by WooYun - CODE BLUE 2015
New immune system of information security from CHINA by WooYun - CODE BLUE 2015New immune system of information security from CHINA by WooYun - CODE BLUE 2015
New immune system of information security from CHINA by WooYun - CODE BLUE 2015CODE BLUE
 

En vedette (16)

Drug Activity
Drug Activity Drug Activity
Drug Activity
 
2016-02 Toxicidades de los nuevos fármacos en cáncer renal
2016-02 Toxicidades de los nuevos fármacos en cáncer renal2016-02 Toxicidades de los nuevos fármacos en cáncer renal
2016-02 Toxicidades de los nuevos fármacos en cáncer renal
 
読書のススメ
読書のススメ読書のススメ
読書のススメ
 
日外アソシエーツ データベースカンパニーの歩み
日外アソシエーツ データベースカンパニーの歩み日外アソシエーツ データベースカンパニーの歩み
日外アソシエーツ データベースカンパニーの歩み
 
Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...
Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...
Lenvatinib-suppresses-angiogenesis-through-the-inhibition-of-both-the-vegfr-a...
 
免疫系統
免疫系統免疫系統
免疫系統
 
Try Jetpack
Try JetpackTry Jetpack
Try Jetpack
 
nakihiro_rengo2015
nakihiro_rengo2015nakihiro_rengo2015
nakihiro_rengo2015
 
岡山スマホアプリ開発もくもく会 #oso2016
岡山スマホアプリ開発もくもく会 #oso2016岡山スマホアプリ開発もくもく会 #oso2016
岡山スマホアプリ開発もくもく会 #oso2016
 
中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015
中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015
中国における情報セキュリティの新たな免疫システムの作り方 by WooYun - CODE BLUE 2015
 
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
 
HEOR and HTA for Market Access and Value Propositions
HEOR and HTA for Market Access and Value PropositionsHEOR and HTA for Market Access and Value Propositions
HEOR and HTA for Market Access and Value Propositions
 
20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業
20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業
20160210中央会計インターンンシップ:チーム7 バングラデシュの初等教育事業
 
Vasculitis 2013
Vasculitis 2013Vasculitis 2013
Vasculitis 2013
 
New immune system of information security from CHINA by WooYun - CODE BLUE 2015
New immune system of information security from CHINA by WooYun - CODE BLUE 2015New immune system of information security from CHINA by WooYun - CODE BLUE 2015
New immune system of information security from CHINA by WooYun - CODE BLUE 2015
 
調節性T細胞
調節性T細胞調節性T細胞
調節性T細胞
 

Similaire à 疑似免疫缺陷immunodeficiency (郭和昌醫師)

03 15-艾滋病
03 15-艾滋病03 15-艾滋病
03 15-艾滋病yansongfan
 
Vaccines And Immunization
Vaccines And ImmunizationVaccines And Immunization
Vaccines And Immunizationstarlviola
 
眼科臨床診斷學
眼科臨床診斷學眼科臨床診斷學
眼科臨床診斷學doc30845
 
新樓醫院醫師講座20080425
新樓醫院醫師講座20080425新樓醫院醫師講座20080425
新樓醫院醫師講座20080425鈉泰 葉
 
CAP诊断与治疗
CAP诊断与治疗CAP诊断与治疗
CAP诊断与治疗lilongyun
 
高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思
高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思
高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思J Yeo
 
乙肝疫苗以及乙肝防治知识
乙肝疫苗以及乙肝防治知识乙肝疫苗以及乙肝防治知识
乙肝疫苗以及乙肝防治知识bdg365
 
郎景和:重视疑难内异症的临床与基础研究
郎景和:重视疑难内异症的临床与基础研究郎景和:重视疑难内异症的临床与基础研究
郎景和:重视疑难内异症的临床与基础研究hbccsc
 
郭國華博士抗癌機轉原理+實驗
郭國華博士抗癌機轉原理+實驗郭國華博士抗癌機轉原理+實驗
郭國華博士抗癌機轉原理+實驗jimmy1013
 
1120119-小兒科病例討論會.pdf
1120119-小兒科病例討論會.pdf1120119-小兒科病例討論會.pdf
1120119-小兒科病例討論會.pdfKs doctor
 
112/05/12-感染症的最新診斷技術.pdf
112/05/12-感染症的最新診斷技術.pdf112/05/12-感染症的最新診斷技術.pdf
112/05/12-感染症的最新診斷技術.pdfKs doctor
 
醫學檢查小常識
醫學檢查小常識醫學檢查小常識
醫學檢查小常識lys167
 
疫苗臨床試驗的挑戰與契機
疫苗臨床試驗的挑戰與契機疫苗臨床試驗的挑戰與契機
疫苗臨床試驗的挑戰與契機hprc_tmu
 

Similaire à 疑似免疫缺陷immunodeficiency (郭和昌醫師) (20)

03 15-艾滋病
03 15-艾滋病03 15-艾滋病
03 15-艾滋病
 
Vaccines And Immunization
Vaccines And ImmunizationVaccines And Immunization
Vaccines And Immunization
 
眼科臨床診斷學
眼科臨床診斷學眼科臨床診斷學
眼科臨床診斷學
 
新樓醫院醫師講座20080425
新樓醫院醫師講座20080425新樓醫院醫師講座20080425
新樓醫院醫師講座20080425
 
CAP诊断与治疗
CAP诊断与治疗CAP诊断与治疗
CAP诊断与治疗
 
高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思
高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思
高雄醫師會誌110期~醫政廣場 | 呂聆音:自體免疫因子判讀之意義與迷思
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
乙肝疫苗以及乙肝防治知识
乙肝疫苗以及乙肝防治知识乙肝疫苗以及乙肝防治知识
乙肝疫苗以及乙肝防治知识
 
郎景和:重视疑难内异症的临床与基础研究
郎景和:重视疑难内异症的临床与基础研究郎景和:重视疑难内异症的临床与基础研究
郎景和:重视疑难内异症的临床与基础研究
 
郭國華博士抗癌機轉原理+實驗
郭國華博士抗癌機轉原理+實驗郭國華博士抗癌機轉原理+實驗
郭國華博士抗癌機轉原理+實驗
 
類風濕性關節炎治療策略管理
類風濕性關節炎治療策略管理類風濕性關節炎治療策略管理
類風濕性關節炎治療策略管理
 
1120119-小兒科病例討論會.pdf
1120119-小兒科病例討論會.pdf1120119-小兒科病例討論會.pdf
1120119-小兒科病例討論會.pdf
 
112/05/12-感染症的最新診斷技術.pdf
112/05/12-感染症的最新診斷技術.pdf112/05/12-感染症的最新診斷技術.pdf
112/05/12-感染症的最新診斷技術.pdf
 
醫學檢查小常識
醫學檢查小常識醫學檢查小常識
醫學檢查小常識
 
疫苗臨床試驗的挑戰與契機
疫苗臨床試驗的挑戰與契機疫苗臨床試驗的挑戰與契機
疫苗臨床試驗的挑戰與契機
 
9. rheumatoid arthritis liu liang
9. rheumatoid arthritis   liu liang9. rheumatoid arthritis   liu liang
9. rheumatoid arthritis liu liang
 
簡報1030726
簡報1030726簡報1030726
簡報1030726
 
2015.04.25. 劉峰誠.為甚麼持續治療很重要
2015.04.25. 劉峰誠.為甚麼持續治療很重要2015.04.25. 劉峰誠.為甚麼持續治療很重要
2015.04.25. 劉峰誠.為甚麼持續治療很重要
 
2015.04.25. 劉峰誠.為甚麼持續治療很重要
2015.04.25. 劉峰誠.為甚麼持續治療很重要2015.04.25. 劉峰誠.為甚麼持續治療很重要
2015.04.25. 劉峰誠.為甚麼持續治療很重要
 
基金會衛教20160813 sle-3
基金會衛教20160813 sle-3基金會衛教20160813 sle-3
基金會衛教20160813 sle-3
 

Plus de Ho-Chang Kuo (郭和昌 醫師)

IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)
IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)
IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)Ho-Chang Kuo (郭和昌 醫師)
 
Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)
Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)
Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)Ho-Chang Kuo (郭和昌 醫師)
 
Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)
Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)
Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)Ho-Chang Kuo (郭和昌 醫師)
 
2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 
2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 
2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 Ho-Chang Kuo (郭和昌 醫師)
 
Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)
Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)
Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)Ho-Chang Kuo (郭和昌 醫師)
 
Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師
Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師
Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師Ho-Chang Kuo (郭和昌 醫師)
 
Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師
Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師
Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師Ho-Chang Kuo (郭和昌 醫師)
 
嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師
嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師
嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師Ho-Chang Kuo (郭和昌 醫師)
 
New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師
New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師
New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師Ho-Chang Kuo (郭和昌 醫師)
 
Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症
Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症
Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症Ho-Chang Kuo (郭和昌 醫師)
 

Plus de Ho-Chang Kuo (郭和昌 醫師) (12)

2011 j hum genet 161-5
2011 j hum genet 161-52011 j hum genet 161-5
2011 j hum genet 161-5
 
IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)
IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)
IVIG brands and eosinophil in Kawasaki disease (郭和醫師 川崎症)
 
Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)
Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)
Persistent monocytosis and CAL in Kawasaki disease, Ho-Chang Kuo, MD (郭和昌醫師 川崎症)
 
Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)
Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)
Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)
 
2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 
2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 
2010台灣醫界--幼年型類風濕性關節炎--郭和昌醫師 
 
Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)
Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)
Predict of coronary artery lesions in Kawasaki disease (川崎症-郭和昌醫師)
 
Pediatr allergy immunol 2009 20 266 272
Pediatr allergy immunol 2009 20 266 272Pediatr allergy immunol 2009 20 266 272
Pediatr allergy immunol 2009 20 266 272
 
Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師
Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師
Treatment of Pediatric asthma-(Ho-Chang Kuo, MD)郭和昌醫師
 
Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師
Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師
Kawasaki disesae review (Ho-Chang Kuo, MD)郭和昌醫師
 
嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師
嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師
嬰幼兒過敏介紹與預防(Allergy disease, How to prevent)郭和昌醫師
 
New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師
New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師
New Concept Of Kawasaki Disease By Ho-Chang Kuo 2008(川崎症)郭和昌醫師
 
Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症
Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症
Ivig Resistent In Kawasaki Disease By Ho Chang Kuo (郭和昌)川崎症
 

疑似免疫缺陷immunodeficiency (郭和昌醫師)

Notes de l'éditeur

  1. T cell  PCP or fungus infection  <3m/o B cell  >6m/0 S/S develp  bacterial inection and URI Neutrophil  present at any age with skin infection, abscess, lymphadenopathy Complement  general inection with encapsulated orgen 
  2. T cell  PCP or fungus infection  <3m/o B cell  >6m/0 S/S develp  bacterial inection and URI Neutrophil  present at any age with skin infection, abscess, lymphadenopathy Complement  general inection with encapsulated orgen 
  3. T cell  PCP or fungus infection  <3m/o B cell  >6m/0 S/S develp  bacterial inection and URI Neutrophil  present at any age with skin infection, abscess, lymphadenopathy Complement  general inection with encapsulated orgen 
  4. T cell  PCP or fungus infection  <3m/o B cell  >6m/0 S/S develp  bacterial inection and URI Neutrophil  present at any age with skin infection, abscess, lymphadenopathy Complement  general inection with encapsulated orgen 
  5. The microscopic nitroblue tetrazolium (NBT) slide test, used to score the ability of individual phagocytic leukocytes to produce superoxide Purified granulocyte suspensions are incubated with NBT and fixed in suspension, thereafter centrifuged on microscope slides and stained with nuclear fast red. This method precludes stimulation and selection of cells by adherence and washing. The number of formazan grains per cell can be judged in a semiquantitative way. In parallel incubations, the cells are stained with May-Grunwald/Giemsa, allowing identification of formazan-positive and -negative cells. The test discriminates well between cells from normal individuals, cells from patients with chronic granulomatous disease ( CGD ), and cells from heterozygotes for the X-linked form of CGD . Several patients and heterozygotes with an autosomal or variant form of CGD were detected with decreased NBT-reducing activity in their neutrophils and/or eosinophils. The relation between NBT-reductase activity of the phagocytes and the clinical situation is discussed.
  6. 1.IgA deficiency is the most common B cell defect
  7. 1.IgA deficiency is the most common B cell defect
  8. 1.IgA deficiency is the most common B cell defect
  9. 1.IgA deficiency is the most common B cell defect
  10. 1.IgA deficiency is the most common B cell defect